Key result
Intravenous recombinant tissue plasminogen activator utilization for acute ischemic stroke in the United States increased from 1.3% in 2001 to 3.5% in 2008.
Why the study?
What are the trends in utilization and predictors of outcomes for intravenous recombinant tissue plasminogen activator in acute ischemic stroke?
Population
Patients with a primary diagnosis of acute ischemic stroke in the United States
Design
Cohort
Follow-up
in-hospital
Authors
Loading...
Supports rising rtPA adoption in AIS; leaves open impact on outcomes amid persistent predictors like age and AF.
Observational
Yes
What are the trends in utilization and predictors of outcomes for intravenous recombinant tissue plasminogen activator in acute ischemic stroke?
Absolute Event Rate: 3.5% vs 1.3%
Utilization of intravenous rtPA for acute ischemic stroke increased significantly between 2001 and 2008 in the US, though advanced age and comorbidities like atrial fibrillation remain strong predictors of adverse outcomes.
Nasr et al. (2012) conducted an observational in acute ischemic stroke. Intravenous recombinant tissue plasminogen activator was evaluated on Utilization rate of intravenous recombinant tissue plasminogen activator. Intravenous recombinant tissue plasminogen activator utilization for acute ischemic stroke in the United States increased from 1.3% in 2001 to 3.5% in 2008.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: